Literature DB >> 15788007

Tumour staging, morphology and p53 overexpression concur in predicting survival in hepatocellular carcinoma.

S Gianni1, A Cecchetto, G Altavilla, R Ragazzi, M Bertazzo, M De Giorgio, A Baldan, S Fagiuoli, F Farinati.   

Abstract

BACKGROUND/AIMS: The prognosis of hepatocellular carcinoma (HCC) on cirrhosis is hard to predict as it depends on tumour stage, underlying liver disease, type of treatment and, possibly, biological factors of the tumour itself.
METHODS: We prospectively evaluated the survival of 91 consecutive patients with HCC on cirrhosis, diagnosed between January 1998 and December 1999. Clinical features and histological/biological aspects, including histotype, grade, p53 overexpression, cytoproliferation and apoptotic markers were analysed.
RESULTS: Child-Pugh (P = 0.01), Okuda (P < 0.0001), Cancer of the Liver Italian Program (CLIP) staging (P < 0.0001) and type of treatment (P = 0.0001) were significantly related to survival. In the Cox model, CLIP staging was included as independent predictor of survival at step 1 (P < 0.0001) with Okuda at step 2 (P = 0.013). Amongst the biological factors, p53 overexpression and histotype were significantly related with survival (P = 0.0044 and 0.017 respectively). When clinical and biological variables were examined together in the Cox model, CLIP and Okuda were confirmed as being statistically related with survival (P < 0.0001 and =0.012) followed by histotype and p53 overexpression (P = 0.019 and 0.02).
CONCLUSIONS: CLIP, Okuda, histotype and p53 overexpression are the strongest predictors of survival in this series of patients. These data confirm that staging of the tumour and underlying liver disease are strictly related to prognosis but support the concurrent role of clinical and biological factors in upgrading our capacity of predicting the fate of HCC patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15788007     DOI: 10.1111/j.1365-2796.2005.01460.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  5 in total

1.  TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Jun Xue
Journal:  Tumour Biol       Date:  2014-02

Review 2.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

Review 3.  Serum tumor markers for detection of hepatocellular carcinoma.

Authors:  Lin Zhou; Jia Liu; Feng Luo
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

4.  Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

5.  Causal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFκB Signaling in Hepatocellular Carcinoma.

Authors:  Julia C Engelmann; Thomas Amann; Birgitta Ott-Rötzer; Margit Nützel; Yvonne Reinders; Jörg Reinders; Wolfgang E Thasler; Theresa Kristl; Andreas Teufel; Christian G Huber; Peter J Oefner; Rainer Spang; Claus Hellerbrand
Journal:  PLoS Comput Biol       Date:  2015-05-28       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.